Results 21 to 30 of about 41,221 (142)

Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience [PDF]

International Journal of Molecular Sciences
Marco Salvetti, Gianmarco Bellucci, Maria Chiara Buscarinu   +2 more
exaly   +2 more sources

Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma. [PDF]

Clin Pharmacol Ther
Extended interval dosing regimens of immune checkpoint inhibitors have been implemented widely. However, their approval was mainly based on pharmacokinetic modeling and simulations. Consequently, comparative safety data of extended interval dosing regimens in a real‐world setting are limited.
Malmberg R, Hofman MM, Ashad F, Daloul A, Oosterveld S, Basak EA, Oomen-de Hoop E, van der Veldt AAM, Joosse A, van Leeuwen RWF, Mathijssen RHJ.   +10 more
europepmc   +4 more sources

Flea and tick treatment satisfaction, preference, and adherence of U.S. cat owners prescribed topical fluralaner (Bravecto® Topical Solution for Cats) [PDF]

Open Veterinary Journal, 2021
Background: Fluralaner is a novel isoxazoline compound and the only systemically distributed ectoparasiticide approved in the United States for re-dosing at up to 12-week intervals for flea and tick control in cats.
Robert Lavan, Dorothy Normile, Rob Armstrong, Wendy Vaala   +3 more
doaj   +1 more source

An extended interval dosing method for gentamicin in neonates [PDF]

Journal of Antimicrobial Chemotherapy, 2001
Traditional gentamicin dosing every 8-24 h depending on age and weight in neonates does not provide the ideal concentration-time profile to both optimize the concentration-dependent killing by aminoglycosides and minimize toxicity. Fifty-three neonates were audited prospectively while receiving gentamicin 2.5 mg/kg every 8-24 h, aiming for peak ...
Stickland, M. D., Kirkpatrick, C., Begg, E., Duffull, S. B., Oddie, S. J., Darlow, B.   +5 more
openaire   +5 more sources

Flea and tick treatment satisfaction, preference, and adherence reported by cat owners in the U.S., U.K., or France who treated their cats with transdermal fluralaner [PDF]

Open Veterinary Journal, 2021
Background: Fluralaner (Bravecto®) is an isoxazoline class compound that is the only topically applied systemic ectoparasiticide approved for dosing at up to 12-week intervals for flea and tick control in cats.
Robert Philip Lavan, Rob Armstrong, Hannah Newbury, Dorothy Normile, Celine Hubinois   +4 more
doaj   +1 more source

No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)

Therapeutic Advances in Neurological Disorders, 2021
Background: Extended interval dosing of natalizumab is associated with significantly lower progressive multifocal leukoencephalopathy risk compared with every-4-week (Q4W) dosing in patients with relapsing-remitting multiple sclerosis.
Helmut Butzkueven, Ludwig Kappos, Tim Spelman, Maria Trojano, Heinz Wiendl, Ray Su, Shirley Liao, Robert Hyde, Stephanie Licata, Pei-Ran Ho, Nolan Campbell   +10 more
doaj   +1 more source

Safety and clinical outcomes of pembrolizumab standard-interval dosing versus extended-interval dosing in patients with breast cancer. [PDF]

Oncologist
Abstract Introduction Extended-interval (EI) dosing of pembrolizumab (400 mg IV every 6 weeks) was approved across all solid tumors based on pharmacokinetic modeling and exposure-response analyses.
LeVee A, Kordic A, Ruel N, Mortimer J, Kang I, McArthur H, Lechner MG, Tsai K.   +7 more
europepmc   +3 more sources

Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved? [PDF]

Neurotherapeutics, 2020
Extending the natalizumab interval after the 24th administration could reduce the risk of progressive multifocal leukoencephalopathy (PML). The objective is to evaluate the noninferiority of the efficacy of an extended interval dosing (EID) compared with the standard interval dosing (SID) of natalizumab.
Clerico, Marinella, De Mercanti, Stefania Federica, Signori, Alessio, Iudicello, Marco, Cordioli, Cinzia, Signoriello, Elisabetta, Lus, Giacomo, Bonavita, Simona, Lavorgna, Luigi, Maniscalco, Giorgia Teresa, Curti, Erica, Lorefice, Lorena, Cocco, Eleonora, Nociti, Viviana, Mirabella, Massimiliano, Baroncini, Damiano, Mataluni, Giorgia, Landi, Doriana, Petruzzo, Martina, Lanzillo, Roberta, Gandoglia, Ilaria, Laroni, Alice, Frangiamore, Rita, Sartori, Arianna, Cavalla, Paola, Costantini, Gianfranco, Sormani, Maria Pia, Capra, Ruggero   +27 more
openaire   +7 more sources

A Meta-Analysis of Extended-Interval Dosing Versus Multiple Daily Dosing of Aminoglycosides [PDF]

Clinical Infectious Diseases, 1997
We conducted a meta-analysis of 22 randomized, controlled trials in which extended-interval dosing of aminoglycosides was compared with multiple daily dosing. When we classified intermediate outcomes as successes, we found that patients receiving extended-interval dosing were at significantly reduced risk of clinical treatment failure (risk difference,
T C, Bailey, J R, Little, B, Littenberg, R M, Reichley, W C, Dunagan   +4 more
openaire   +2 more sources

Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly [PDF]

Endocrine, 2020
Abstract Purpose Recent data indicate that extended dosing intervals (EDIs) with lanreotide autogel 120 mg are effective and well-received among patients with acromegaly who have achieved biochemical control with monthly injections of long-acting somatostatin analogues (SSAs).
Ignacio Bernabéu, Carmen Fajardo, Mónica Marazuela, Fernando Cordido, Eva María Venegas, Pedro de Pablos-Velasco, Gonzalo Piedrola Maroto, María Pilar Olvera, Isabel Pavón de Paz, Davide Carvalho, Carme Romero, Guillermo De la Cruz, Cristina Álvarez Escolá   +12 more
openaire   +7 more sources